New oral drugs for the treatment of multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis
New oral drugs have considerably enriched the therapeutic armamentarium for the treatment of multiple sclerosis. This review focuses on the molecular pharmacodynamics of fingolimod, dimethyl fumarate (BG-12), laquinimod, and teriflunomide. We specifically comment on the action of these drugs at three levels: 1) the regulation of the immune system; 2) the permeability of the blood-brain barrier;...
متن کاملTeriflunomide - a new oral agent for multiple sclerosis treatment.
T eriflunomide is an oral immunomo-du lator, an active metabolite of le-flunomide. Leflunomide is used in the long-term treatment of rheuma-toid arthritis and is metabolized to te riflunomide in vivo. The mechanism of action of teriflunomide is linked to reversibly inhibition of dihydroorotate dehydrogenase, a mithocondrial enzyme involved in de novo synthesis of pyrimidine for DNA replication....
متن کاملP123: Stimulating In Vivo Remyelination (IVR): A New Approach for Multiple Sclerosis Treatment
Multiple sclerosis (MS) is one of the most common neuroinflammatory disorders that causes disability in the young adults. In this disease immune-driven demyelination and following that inefficient remyelination occurs. Therapies for this disease are limited, especially those to enhance myelin repair. Cellular reprogramming using defined genetic factors is a way to produce remyelinating Oligoden...
متن کاملO 8: Tenasin-C as a New Target for Multiple Sclerosis Treatment
Multiple Sclerosis (MS) is an autoimmune disease, which is characterized by demyelination and neuroinflammation. Extracellular Matrix (ECM) have important role in the central nervous system (CNS). Alterations are happening to the ECM after the CNS disorder like MS, Alzheimer and other neural injury. Tenasin-C (TnC) is a glycoprotein that is highly expressed in inflammatory conditions of the CNS...
متن کاملLaquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
Laquinimod, a second-generation quinoline-3-carboxamide, is being developed by Active Biotech AB and Teva Pharmaceutical Industries Ltd for the treatment for relapsing-remitting multiple sclerosis (RRMS). Laquinimod has demonstrated significant activity in suppressing experimental autoimmune encephalomyelitis, an animal model of RRMS. In phase I and II clinical trials, the drug was well tolerat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Hospital Medicine
سال: 2016
ISSN: 1750-8460,1759-7390
DOI: 10.12968/hmed.2016.77.9.502